
USD
( 0.00%
At Close (As of Jan 1, 1970)
$1.57B
Market Cap
-
P/E Ratio
-7.01
EPS
$46.00
52 Week High
$22.24
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $32M |
| Total Revenue | $36M |
| Cost Of Revenue | $4.2M |
| Costof Goods And Services Sold | $4.2M |
| Operating Income | -$426M |
| Selling General And Administrative | $157M |
| Research And Development | $301M |
| Operating Expenses | $458M |
| Investment Income Net | - |
| Net Interest Income | $48M |
| Interest Income | $48M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $5.7M |
| Income Before Tax | $718M |
| Income Tax Expense | $44M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $674M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$426M |
| Ebitda | -$420M |
| Net Income | $674M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $32M |
| Total Revenue | $36M |
| Cost Of Revenue | $4.2M |
| Costof Goods And Services Sold | $4.2M |
| Operating Income | -$426M |
| Selling General And Administrative | $157M |
| Research And Development | $301M |
| Operating Expenses | $458M |
| Investment Income Net | - |
| Net Interest Income | $48M |
| Interest Income | $48M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $5.7M |
| Income Before Tax | $718M |
| Income Tax Expense | $44M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $674M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$426M |
| Ebitda | -$420M |
| Net Income | $674M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Agios Pharmaceuticals, Inc. is a prominent biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to developing transformative therapies targeting diseases related to cellular metabolism. With a strong focus on oncology and rare genetic disorders, Agios utilizes its extensive knowledge of metabolic pathways to create innovative treatments that exemplify precision medicine. The company boasts a promising pipeline and actively engages in strategic collaborations to enhance research and development efforts, demonstrating its commitment to advancing scientific understanding and significantly improving patient outcomes through state-of-the-art therapeutic solutions.